Abstract:Objective:To explore the effect of bromodomain-containing protein 4 (BRD4)on the expression, proliferation, and migration of non-small cell lung cancer (NSCLC) cells with high expression of programmed death ligand 1 (PD-L1).Methods:Relevant data on NSCLC patients were obtained through The Cancer Genome Atlas (TCGA) database in Gene Expression Profiling Interactive Analysis (GEPIA).The overall survival rate of NSCLC patients with high expression of PD-L1 and BRD4 was analyzed, and correlation analysis on the expression of BRD4 and PD-L1 was conducted.The mRNA and protein expression levels of PD-L1 were determined, and cell lines with high expression of PD-L1 were selected for subsequent experiments.A549 cells were transfected with si-NC and si-BRD4, respectively, to obtain NC group and BRD4 knock-down group.Subsequently, the mRNA and protein expression levels of BRD4 and PD-L1 in both groups were detected by real-time fluorescence polymerase chain reaction (RT-PCR) and Western blotting.Colony formation assay was used to detect the proliferation and tumorigenesis ability of cells, and scratch assay was used to detect the migration ability of cells.Meanwhile, the control group and JQ1 group were obtained by adding dimethyl sulfoxide (DMSO) and BRD4 inhibitor JQ1, respectively.Western blotting and Cell Counting Kit-8 (CCK-8) assay were applied to detect the protein expression of PD-L1 and the proliferation of A549 cells of the two groups at 0, 12, 24, 36, and 48 hours, respectively.Results:Poor survival rate was observed in NSCLC patients with high expression of BRD4 or PD-L1 ( χ2 values were 6.538 and 8.258, respectively; all P<0.05).Positive correlation was observed between the expression of BRD4 and PD-L1 ( r=0.57, P<0.05, n=105).The mRNA and protein expression levels of PD-L1 in A459 cells were significantly higher than those in H460 and H1975 cells (Fvalues were 2.58 and 2.67, respectively; all P<0.05).The mRNA and protein expression levels of PD-L1 in A549 cells in BRD4 knock-down group were significantly lower than those in NC group (tvalues were 6.37 and 7.54, respectively; all P<0.05).Knockdown of BRD4 could remarkably reduce the migration, colony formation and growth abilities of A549 cells.As time went on, the expression level of PD-L1 protein in JQ1 group decreased gradually.Since 12 hours, there was a significant difference in the expression level of PD-L1 protein between the two groups (tvalues were 7.25, 8.24, 10.25, and 12.23, respectively; all P<0.05).CCK-8 assay showed that over time, the proliferation ability of A549 cells in JQ1 group gradually reduced.Since 12 hours, significant differences were observed in the proliferation of A549 cells between the two groups (tvalues were 8.86, 12.25, 15.24, 7.586, respectively; all P<0.05). Conclusions:Inhibition of BRD4 suppresses the cellular expression, proliferation, and migration of NSCLC with high expression of PD-L1.

BRD4 Inhibition Suppresses Cell Growth, Migration and Invasion of Salivary Adenoid Cystic Carcinoma

JQ1: a novel potential therapeutic target.

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma

Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms

Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma

Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy

JQ1, a Small Molecule Inhibitor of BRD4, Suppresses Cell Growth and Invasion in Oral Squamous Cell Carcinoma

BRD4 As a Therapeutic Target for Nonfunctioning and Growth Hormone Pituitary Adenoma.

Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail

MicroRNA-4651 Targets Bromodomain-Containing Protein 4 to Inhibit Non-Small Cell Lung Cancer Cell Progression

Effects of bromodomain-containing protein 4 on the expression, proliferation, and migration of non-small cell lung cancer with high expression of programmed death ligand 1

BRD4 Inhibition Sensitizes Cervical Cancer to Radiotherapy by Attenuating DNA Repair.

BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression

Brd4 Inhibition Promotes Trail-Induced Apoptosis By Suppressing The Transcriptional Activity Of Nf-Kappa B In Nsclc

Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)

Identification of 3,5-Dimethylisoxazole Derivatives As BRD4 Inhibitors for the Treatment of Colorectal Cancer.

Targeting BRD4 Attenuates the Stemness and Aggressiveness of Ameloblastoma.

BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.

High level of BRD4 promotes non-small cell lung cancer progression

Design, Synthesis, and Biological Evaluation of Novel 4,4-Difluoro-1-methyl-n, 6-Diphenyl-5, 6-Dihydro-4h-pyrimido [4, 5-B] [1, 2, 4] Triazolo [4, 3-D] [1, 4] Diazepin-8-amine Derivatives As Potential BRD4 Inhibitors.